Business Context and Reporting Period
This Form 8-K, filed on August 11, 2014, reports on events occurring on August 8, 2014, by Intrexon Corporation (the "Registrant"). The filing details the completion of the acquisition of Trans Ova Genetics, L.C. ("Trans Ova"), an Iowa limited liability company, pursuant to an Amended and Restated Membership Interest Purchase Agreement.
Key Financial Metrics and Transaction Details
The transaction consideration and financial terms are as follows:
- Cash Consideration at Closing: $60.0 million paid immediately.
- Stock Consideration: Issuance of 1,444,388 shares of Intrexon common stock, valued at $30.0 million.
- Deferred Cash Payments: $20.0 million payable in three equal installments on the first, second, and third anniversaries of the closing date.
- Total Base Consideration: $110.0 million ($60.0M cash + $30.0M stock + $20.0M deferred).
- Additional Contingent Consideration: Potential payments for forgiven governmental debts owed by Trans Ova and a portion of cash proceeds from pending litigation awards.
- Unregistered Securities: 1,378,631 shares issued to sellers under Rule 506 of Regulation D; 65,757 shares issued to employees under Intrexon's 2013 Omnibus Incentive Plan.
Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for either Intrexon or Trans Ova. Pro forma financial information and audited financial statements for Trans Ova are not included and are scheduled to be filed within 71 days.
Material Changes
The primary material change is the consolidation of Trans Ova into Intrexon Corporation effective August 8, 2014. Intrexon has assumed ownership of all membership interests in Trans Ova. The filing notes that the Purchase Agreement Consideration is subject to further adjustment as described in the agreement.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The filing references a press release (Exhibit 99.1) regarding the closing but does not contain specific forward-looking guidance or management commentary within the text of the 8-K itself.
Risks and Contingencies:
- Contingent Liabilities: Intrexon may be required to pay amounts related to Trans Ova's debts to governmental entities if those debts are forgiven.
- Litigation: Additional consideration is tied to the outcome of currently pending litigation matters involving Trans Ova.
- Regulatory Compliance: Intrexon covenanted to file a registration statement on Form S-3 within seven business days of eligibility and keep it effective for six months to register the common stock issued in the transaction.
Investor Verification Checklist
- Verify the final valuation of the 1,444,388 shares of common stock issued at the time of closing versus the stated $30.0 million value.
- Review the upcoming amendment (due within 71 days) for Trans Ova's audited financial statements and pro forma financial information.
- Monitor the status of pending litigation involving Trans Ova to assess potential additional cash consideration.
- Confirm the filing of the Form S-3 registration statement for the unregistered shares as covenanted.
- Assess the impact of the $20.0 million deferred payment obligation on future cash flows.